TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Kivo Health raised $10 million in Series A financing led by Allumia Ventures, bringing its total funding to $16 million. The Seattle company says it will use the money to expand its virtual COPD care program nationwide and reach tens of thousands of patients within two years; its reported cost and health outcomes have not been independently detailed in the source.
Seattle-based Kivo Health has raised $10 million in Series A financing to expand its virtual home-care program for people with chronic lung disease, starting with COPD. The round, led by Allumia Ventures, brings the company’s total financing to $16 million and is intended to support a nationwide rollout, according to the company’s report to Home Health Care News.
The round also included Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, Home Health Care News reported. Kivo said the funding will help it grow its reach beyond its existing service area. Co-founder and CEO Victor Sadauskas told the publication that the company plans to serve tens of thousands of patients over the next two years.
Kivo’s program pairs home-use equipment and virtual respiratory therapy. After enrolling, a patient receives a kit that includes a tablet, an oxygen monitor and exercise bands. The patient meets online with a respiratory therapist, who assesses symptoms and develops an individual treatment plan, according to the company’s website.
Participants then attend virtual small-group sessions with respiratory therapists twice a week for nine weeks. The program covers breathing techniques, targeted exercises and information about managing COPD. Kivo says its care model is designed to help patients manage symptoms between clinical visits and receive earlier support. Those intended benefits are company claims, not independently verified findings in the source report.
Funding Supports a Wider COPD Program
The investment gives Kivo additional capital to expand a care model that moves some respiratory support into patients’ homes and delivers it remotely. If the company reaches its stated growth goal, more patients may have access to scheduled respiratory-therapy sessions without relying only on in-person appointments. The potential relevance is greatest for people managing COPD, a chronic condition that may require ongoing support between visits to a clinician.
Kivo also says its program can reduce avoidable hospitalizations, emergency department visits and nursing-home days, and claims an annual reduction of $8,245 in total health care spending per member. The report does not provide the methods, comparison group or time period behind that savings estimate. It should be treated as a company-reported figure rather than an independently established result.
For health plans and care providers, the funding signals investor interest in remote programs that combine digital tools with clinician-led services. Whether expansion produces the patient and cost outcomes Kivo describes will depend on evidence and implementation details not included in the funding announcement.
Products Worth Considering
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
As an affiliate, we earn on qualifying purchases.
How Kivo Delivers Care at Home
Kivo focuses on virtual care for chronic lung diseases, beginning with chronic obstructive pulmonary disease. Its approach combines a device kit with repeated contact with respiratory therapists, rather than relying on an app or remote monitoring alone. The company says the program is intended to help older adults receive earlier intervention and manage COPD outside scheduled clinical visits.
According to the report, Kivo’s program is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. The source does not specify which plans cover the program in each location or the eligibility and enrollment rules that apply. Kivo says it plans to extend its care model to other high-cost chronic illnesses, but has not named the conditions or a launch timetable in the material provided.
“We plan to expand nationwide to deliver care to tens of thousands of patients in the next two years.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion and Outcome Data Remain Open
The announcement does not give a detailed rollout schedule, identify the first new markets or explain how the Series A proceeds will be divided among hiring, technology and operations. It is also unclear how many patients Kivo currently serves, where those patients are located, and what the company’s target of tens of thousands means in terms of enrollment or completed treatment.
The source report does not provide clinical study results or independent verification for Kivo’s claims about symptom improvement, avoided hospital use or $8,245 in annual savings per member. Details such as the measurement period, baseline costs and patient population behind the savings estimate are not stated. The announcement also does not name the additional chronic conditions Kivo may address or say when those services could begin.
National Rollout Is the Next Milestone
Kivo says it intends to expand nationwide and reach tens of thousands of patients within two years. The company has not announced a market-by-market schedule in the source report, so the timing and pace of that expansion remain uncertain. Further company updates may clarify where services will be offered and how eligible patients can enroll through participating health plans.
Another expected development is whether Kivo moves beyond COPD to other chronic illnesses. The company has expressed that intention but has not named conditions, launch dates or program details. Information on enrollment, patient outcomes and health care spending would help show how the care model performs as it grows.
Key Questions
How much funding did Kivo Health raise?
Kivo raised $10 million in Series A financing, bringing its total financing to $16 million, according to Home Health Care News.
Who led the funding round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated, the report said.
What does Kivo Health’s program provide?
Kivo’s COPD program combines a home kit, including a tablet and oxygen monitor, with virtual assessments and small-group respiratory-therapy sessions. The company’s website describes a nine-week program with sessions twice weekly.
What does Kivo plan to do with the money?
The company says it will use the financing to expand nationwide and aims to serve tens of thousands of patients in the next two years. It also intends to extend its model to other high-cost chronic illnesses, but has not named them.
Are Kivo’s reported savings independently confirmed?
The source report attributes the claimed annual savings of $8,245 per member to Kivo. It does not provide independent validation or the methods and comparison basis behind that figure.
Source: homehealthcarenews.com
